Epinephrine Concentrate Injection

Name: Epinephrine Concentrate Injection

Drug Interactions

Drugs antagonizing pressor effects of epinephrine

  • α-blockers, such as phentolamine
  • Vasodilators, such as nitrates
  • Diuretics
  • Antihypertensives
  • Ergot alkaloids

Drugs potentiating pressor effects of epinephrine

  • Sympathomimetics
  • β-blockers, such as propranolol
  • Tricyclic anti-depressants
  • Monoamine oxidase (MAO) inhibitors
  • Catechol-O-methyl transferase (COMT) inhibitors, such as entacapone
  • Clonidine
  • Doxapram
  • Oxytocin

Drugs potentiating arrhythmogenic effects of epinephrine. Patients who are concomitantly receiving any of the following drugs should be observed carefully for the development of cardiac arrhythmias [see Warnings and Precautions (5.6) and Adverse Reactions (6)].

  • β-blockers, such as propranolol
  • Cyclopropane or halogenated hydrocarbon anesthetics, such as halothane
  • Antihistamines
  • Thyroid hormones
  • Diuretics
  • Cardiac glycosides, such as digitalis glycosides
  • Quinidine

Drugs potentiating hypokalemic effects of epinephrine

  • Potassium depleting diuretics
  • Corticosteroids
  • Theophylline

Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine may result in further lowering of blood pressure.

Epinephrine may antagonize the neuronal blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.

Epinephrine Concentrate Injection - Clinical Pharmacology

Mechanism of Action

Epinephrine acts on both alpha (α)- and beta (β)-adrenergic receptors. The mechanism of the rise in blood pressure is 3-fold: a direct myocardial stimulation that increases the strength of ventricular contraction (positive inotropic action), an increased heart rate (positive chronotropic action), and peripheral vasoconstriction.

Pharmacodynamics

Intravenous use for hypotension associated with septic shock:

Following intravenous administration of epinephrine, increases in systolic blood pressure and heart rate are observed. Decreases in systemic vascular resistance and diastolic blood pressure are observed at low doses of epinephrine because of β2-mediated vasodilation, but are overtaken by α1-mediated peripheral vasoconstriction at higher doses leading to increase in diastolic blood pressure. The onset of blood pressure increase following an intravenous dose of epinephrine is < 5 minutes and the time to offset blood pressure response occurs within 20 min. Most vascular beds are constricted including renal, splanchnic, mucosal and skin.

Intramuscular and subcutaneous use for anaphylaxis

Through its action on alpha-adrenergic receptors, epinephrine lessens the vasodilation and increased vascular permeability that occurs during anaphylaxis, which can lead to loss of intravascular fluid volume and hypotension.

Through its action on beta-adrenergic receptors, epinephrine causes bronchial smooth muscle relaxation and helps alleviate bronchospasm, wheezing and dyspnea that may occur during anaphylaxis.

Epinephrine also alleviates pruritus, urticaria, and angioedema and may relieve gastrointestinal and genitourinary symptoms associated with anaphylaxis because of its relaxer effects on the smooth muscle of the stomach, intestine, uterus and urinary bladder.

Epinephrine increases glycogenolysis, reduces glucose up take by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia and increased blood lactic acid [see Warnings and Precautions (5.9)].

Intraocular use for mydriasis

Epinephrine causes mydriasis when administered intraocularly or parenterally.

Pharmacokinetics

When administered parenterally or intraocularly, epinephrine has a rapid onset and short duration of action.

Following intravenous injection, epinephrine is rapidly cleared from the plasma with an effective half-life of < 5 min. A pharmacokinetic steady state following continuous intravenous infusion is achieved within 10-15 min. In patients with septic shock, epinephrine displays dose-proportional pharmacokinetics in the infusion dose range of 0.03 to 1.7 mcg/kg/min.

The extent of human systemic exposure at the labeled intraocular dose has not been evaluated, however, significant systemic concentrations or plasma exposure of epinephrine are not expected when administered intraocularly.

Epinephrine is extensively metabolized with only a small amount excreted unchanged.

Epinephrine is rapidly degraded to vanillylmandelic acid, an inactive metabolite, by monoamine oxidase and catechol-O-methyltransferase that are abundantly expressed in the liver, kidneys and other extraneuronal tissues. The tissues with the highest contribution to removal of circulating exogenous epinephrine are the liver (32%), kidneys (25%), skeletal muscle (20%), and mesenteric organs (12%).

Special Populations

Elderly

In a pharmacokinetic study of 45-minute epinephrine infusions given to healthy men aged 20 to 25 years and healthy men aged 60 to 65 years, the mean plasma metabolic clearance rate of epinephrine at steady state was greater among the older men (144.8 versus 78 mL/kg/min for a 14.3 ng/kg/min infusion).

Body Weight

Body weight has been found to influence epinephrine pharmacokinetics. Higher body weight was associated with a higher plasma epinephrine clearance and a lower concentration plateau.

Patient Counseling Information

Advise patients or their caregivers about common adverse reactions associated with the use of epinephrine, including an increase in heart rate, the sensation of a more forceful heartbeat, palpitations, sweating, nausea and vomiting, difficulty breathing, pallor, dizziness, weakness or shakiness, headache, apprehension, nervousness, or anxiety. These symptoms and signs usually subside rapidly, especially with rest, quiet and recumbent positioning.

Warn patients with a good response to initial treatment about the possibility of recurrence of anaphylaxis symptoms and instruct patients to obtain medical attention if symptoms return.

Advise patients with diabetes that they may develop increased blood glucose levels following epinephrine administration.

Rare cases of serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia (gas gangrene), have been reported at the injection site following epinephrine injection for anaphylaxis. Advise patients to seek medical care if they develop signs or symptoms of infection, such as persistent redness, warmth, swelling, or tenderness, at the epinephrine injection site [see Warnings and Precautions (5.8)].

Revised: February 2017     L103I      R-1704

Manufactured for:

BPI Labs, LLC, Freehold, NJ 07728 USA

Manufactured by:

Sintetica SA
Via Penate 5
6850 Mendrisio, Switzerland

Epinephrine Injection, USP
1 mg/mL

NDC 54288-103-10


Dilute before Intravenous and Intraocular use.
For Intravenous Infusion, Intramuscular and Subcutaneous Use, and Intraocular Use

Usual Dose: See insert labeling

Each mL contains:
1 mg Epinephrine,
Sodium Chloride 9 mg, Water for Injection, USP
pH adjusted with Hydrochloric Acid.

WARNING: Do not use the solution if it is colored or cloudy, or if it contains particulate matter.

10 Single-Use Ampules x 1mL

CONTAINS NO SULFITES OR PRESERVATIVES

Rev. R-1702

LOT
EXP

EPINEPHRINE 
epinephrine injection, solution, concentrate
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:54288-103
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Epinephrine (Epinephrine) Epinephrine 1 mg  in 1 mL
Inactive Ingredients
Ingredient Name Strength
Sodium Chloride 9 mg  in 1 mL
Hydrochloric Acid  
Water  
Packaging
# Item Code Package Description
1 NDC:54288-103-10 10 AMPULE in 1 BOX
1 1 mL in 1 AMPULE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA205029 08/08/2014
Labeler - BPI Labs, LLC (078627620)
Establishment
Name Address ID/FEI Operations
Sintetica SA 480895478 MANUFACTURE(54288-103), LABEL(54288-103), PACK(54288-103), ANALYSIS(54288-103)
Establishment
Name Address ID/FEI Operations
Sintetica-Bioren SA 483148768 ANALYSIS(54288-103)
Establishment
Name Address ID/FEI Operations
Boehringer Ingelheim Pharma GmbH & Co. 551147440 API MANUFACTURE(54288-103), ANALYSIS(54288-103)
Revised: 02/2017   BPI Labs, LLC
(web3)